IL81018A - Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process - Google Patents
Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the processInfo
- Publication number
- IL81018A IL81018A IL81018A IL8101886A IL81018A IL 81018 A IL81018 A IL 81018A IL 81018 A IL81018 A IL 81018A IL 8101886 A IL8101886 A IL 8101886A IL 81018 A IL81018 A IL 81018A
- Authority
- IL
- Israel
- Prior art keywords
- fragments
- fusion proteins
- ballast
- genes
- vectors
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 title 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 title 1
- 102000055277 human IL2 Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 3
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Suitable as "ballast portion" for fusion proteins is a part of the amino-acid sequence of interleukin-2 (IL-2) which comprises considerably less than 100 amino acids. It is advantageous to start from a synthetic IL-2 gene which is divided by unique cleavage sites into six segments of which up to three can be linked in any desired sequence by the building block principle. Specific constructions allowing the solubility of the fusion protein to be varied are possible.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3545565 | 1985-12-21 | ||
| DE19863636903 DE3636903A1 (en) | 1985-12-21 | 1986-10-30 | FUSION PROTEINS WITH EUKARYOTIC BALLASTES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL81018A0 IL81018A0 (en) | 1987-03-31 |
| IL81018A true IL81018A (en) | 1992-03-29 |
Family
ID=25839208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL81018A IL81018A (en) | 1985-12-21 | 1986-12-18 | Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0229998B1 (en) |
| JP (2) | JP2553058B2 (en) |
| KR (1) | KR950000301B1 (en) |
| AT (1) | ATE78296T1 (en) |
| AU (1) | AU599943B2 (en) |
| CA (1) | CA1339894C (en) |
| DE (1) | DE3636903A1 (en) |
| DK (1) | DK168823B1 (en) |
| ES (1) | ES2033678T3 (en) |
| FI (1) | FI93734C (en) |
| GR (1) | GR3005985T3 (en) |
| HU (1) | HU209747B (en) |
| IE (1) | IE58935B1 (en) |
| IL (1) | IL81018A (en) |
| NO (1) | NO175003C (en) |
| PT (1) | PT83973B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3545568A1 (en) * | 1985-12-21 | 1987-07-16 | Hoechst Ag | GM-CSF-PROTEIN, ITS DERIVATIVES, PRODUCTION OF SUCH PROTEINS AND THEIR USE |
| DE3844211A1 (en) * | 1988-12-29 | 1990-07-05 | Hoechst Ag | NEW INSULINE DERIVATIVES, THE PROCESS FOR THEIR PRODUCTION, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM |
| FR2643646B1 (en) * | 1989-02-27 | 1993-09-17 | Pasteur Institut | EXPRESSION OF NUCLEOTIDES SEQUENCES ENCODING FOR GAS VESICLES |
| CU22222A1 (en) * | 1989-08-03 | 1995-01-31 | Cigb | PROCEDURE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS PRODUCED IN A FUSION FORM IN ESCHERICHIA COLI, ITS USE, EXPRESSION VECTORS AND RECOMBINANT STRAINS |
| DE3942580A1 (en) * | 1989-12-22 | 1991-06-27 | Basf Ag | METHOD FOR PRODUCING HIRUDINE |
| DE4105480A1 (en) * | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | IMPROVED ACTIVATION OF RECOMBINANT PROTEINS |
| DE59711533D1 (en) | 1996-07-26 | 2004-05-27 | Aventis Pharma Gmbh | Insulin derivatives with increased zinc binding |
| DE19825447A1 (en) | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | New insulin analogues with increased zinc formation |
| DE102006031955A1 (en) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Process for the preparation of dibasic B chain end insulin analogs |
| DE102006031962A1 (en) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidated insulin glargine |
| PT3228320T (en) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combination of an insulin and a glp-1 agonist |
| KR101853606B1 (en) | 2009-07-06 | 2018-05-03 | 사노피-아벤티스 도이칠란트 게엠베하 | Aqueous insulin preparations containing methionine |
| DK2498802T3 (en) | 2009-11-13 | 2015-04-13 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine |
| KR101337322B1 (en) | 2009-11-13 | 2013-12-06 | 사노피-아벤티스 도이칠란트 게엠베하 | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| ES2606554T3 (en) | 2010-08-30 | 2017-03-24 | Sanofi-Aventis Deutschland Gmbh | Use of AVE0010 for the manufacture of a medication for the treatment of type 2 diabetes mellitus |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| PL2750699T3 (en) | 2011-08-29 | 2015-12-31 | Sanofi Aventis Deutschland | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| AR087744A1 (en) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE |
| AU2015359376B2 (en) | 2014-12-12 | 2021-09-09 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
| TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
| KR20200080748A (en) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | A Method for Purifying Proinsulin Using Anion Exchange Chromatography |
| KR20200080747A (en) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK108685A (en) * | 1984-03-19 | 1985-09-20 | Fujisawa Pharmaceutical Co | GROWTH FACTOR I |
| EP0158198A1 (en) * | 1984-03-29 | 1985-10-16 | Takeda Chemical Industries, Ltd. | DNA and use thereof |
| GB8412517D0 (en) * | 1984-05-16 | 1984-06-20 | Nagai K | Recombinant fusion proteins |
-
1986
- 1986-10-30 DE DE19863636903 patent/DE3636903A1/en not_active Withdrawn
- 1986-12-16 AT AT86117481T patent/ATE78296T1/en not_active IP Right Cessation
- 1986-12-16 EP EP86117481A patent/EP0229998B1/en not_active Expired - Lifetime
- 1986-12-16 ES ES198686117481T patent/ES2033678T3/en not_active Expired - Lifetime
- 1986-12-18 FI FI865187A patent/FI93734C/en not_active IP Right Cessation
- 1986-12-18 IL IL81018A patent/IL81018A/en not_active IP Right Cessation
- 1986-12-19 PT PT83973A patent/PT83973B/en unknown
- 1986-12-19 NO NO865192A patent/NO175003C/en not_active IP Right Cessation
- 1986-12-19 DK DK619186A patent/DK168823B1/en not_active IP Right Cessation
- 1986-12-19 HU HU865354A patent/HU209747B/en unknown
- 1986-12-19 CA CA000525858A patent/CA1339894C/en not_active Expired - Lifetime
- 1986-12-19 IE IE333486A patent/IE58935B1/en not_active IP Right Cessation
- 1986-12-19 AU AU66760/86A patent/AU599943B2/en not_active Expired
- 1986-12-20 KR KR1019860011010A patent/KR950000301B1/en not_active Expired - Lifetime
- 1986-12-22 JP JP61306185A patent/JP2553058B2/en not_active Expired - Lifetime
-
1992
- 1992-10-15 GR GR920402187T patent/GR3005985T3/el unknown
-
1995
- 1995-10-11 JP JP7263310A patent/JP2774260B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NO175003B (en) | 1994-05-09 |
| JPH08187089A (en) | 1996-07-23 |
| KR950000301B1 (en) | 1995-01-13 |
| DK168823B1 (en) | 1994-06-20 |
| EP0229998A2 (en) | 1987-07-29 |
| AU599943B2 (en) | 1990-08-02 |
| ES2033678T3 (en) | 1993-04-01 |
| GR3005985T3 (en) | 1993-06-07 |
| NO175003C (en) | 1994-08-17 |
| DE3636903A1 (en) | 1987-07-02 |
| HU209747B (en) | 1994-10-28 |
| JP2774260B2 (en) | 1998-07-09 |
| PT83973A (en) | 1987-01-01 |
| AU6676086A (en) | 1987-06-25 |
| KR870006187A (en) | 1987-07-09 |
| CA1339894C (en) | 1998-06-02 |
| DK619186A (en) | 1987-06-22 |
| NO865192L (en) | 1987-06-22 |
| JP2553058B2 (en) | 1996-11-13 |
| ATE78296T1 (en) | 1992-08-15 |
| IE863334L (en) | 1987-06-21 |
| FI93734B (en) | 1995-02-15 |
| FI865187A0 (en) | 1986-12-18 |
| EP0229998A3 (en) | 1988-08-03 |
| HUT44614A (en) | 1988-03-28 |
| NO865192D0 (en) | 1986-12-19 |
| FI93734C (en) | 1995-05-26 |
| EP0229998B1 (en) | 1992-07-15 |
| DK619186D0 (en) | 1986-12-19 |
| FI865187L (en) | 1987-06-22 |
| IL81018A0 (en) | 1987-03-31 |
| IE58935B1 (en) | 1993-12-01 |
| JPS62167799A (en) | 1987-07-24 |
| PT83973B (en) | 1989-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3005985T3 (en) | ||
| HUT43629A (en) | Process for producing fusion proteins | |
| NZ218332A (en) | Il-4(interleukin-4), recombinant production, dna, vectors and pharmaceutical composition | |
| NO875136L (en) | HORSES - GAMMA - INTERFERON. | |
| DK0652903T3 (en) | New human recombinant gamma interferon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |